1. Scrip
  2. >>Business
  3. >>Deals

J&J Gets Into The Anti-TSLP Game With Proteologix Buyout

 
• By Joseph Haas

The privately held biotech will bring J&J a pair of bispecific antibodies expected to target multiple pathologic pathways in atopic dermatitis and asthma.

Deal (Sergey Nivens/Shutterstock.com)
J&J makes its second biopharma acquisition of the year with Proteologix deal

Interest in the anti-TSLP space continued on 16 May with Johnson & Johnson agreeing to pay $850m up front to acquire privately held Proteologix Inc. and its pipeline of bispecific antibodies, led by a Phase I-ready candidate that targets both IL-13 and the thymic stromal lymphopoietin (TSLP) pathway.

Key Takeaways

  • J&J will pay $850m to acquire Proteologix and its pipeline of bispecific antibodies for dermatologic and respiratory indications.

  • Lead candidate PTX128 is ready for Phase I in atopic dermatitis and asthma, and targets both IL-13 and the TSLP pathway

J&J said it intends to develop that lead candidate – PTX128 – in both moderate-to-severe atopic dermatitis and moderate-to-severe asthma. Second in Proteologix’s pipeline is preclinical PTX130, which targets IL-13 and IL-22 and is also under development as a potential therapy in moderate-to-severe AD

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from Business

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.